Subjects: Severity of Illness Index and Cost-Benefit Analysis / Titles: Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Severity of Illness Index ✖ Subjects Cost-Benefit Analysis ✖ Titles Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report ✖

1. Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report

Author(s):: Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Chapman, Rick, author
Shore, Karen K., author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:: [Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016
Subject(s):: Blood Glucose -- drug effects
Diabetes Mellitus, Type 1 -- drug therapy
Diabetes Mellitus, Type 2 -- drug therapy
Hypoglycemia -- prevention & control
Hypoglycemic Agents -- therapeutic use
Insulin, Long-Acting -- administration & dosage
Insulin, Long-Acting -- therapeutic use
Blood Glucose -- metabolism
Cost-Benefit Analysis
Diabetes Mellitus, Type 1 -- blood
Diabetes Mellitus, Type 1 -- complications
Diabetes Mellitus, Type 2 -- blood
Diabetes Mellitus, Type 2 -- complications
Hypoglycemia -- blood
Hypoglycemia -- chemically induced
Hypoglycemic Agents -- administration & dosage
Insulin -- adverse effects
Severity of Illness Index
Humans
United States